<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02222922</url>
  </required_header>
  <id_info>
    <org_study_id>B7661001</org_study_id>
    <secondary_id>2014-003296-36</secondary_id>
    <nct_id>NCT02222922</nct_id>
  </id_info>
  <brief_title>A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors</brief_title>
  <official_title>A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647020 In Adult Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients
      with advanced solid tumors in order to determine the maximum tolerated dose and select the
      recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 17, 2014</start_date>
  <completion_date type="Anticipated">November 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 7, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Dose-limiting toxicities (DLT) {Part1}</measure>
    <time_frame>Day 1 up to Day 21</time_frame>
    <description>First cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Q2W participants with Dose-limiting toxicities (DLT) {Part1}</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>First cycle DLTs in order to determine maximum tolerated dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Days 1, 15, 21, and every 21 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-PF-06647020 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 1)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of response rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response (Part 2)</measure>
    <time_frame>Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of overall response rate (ORR) and progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020 [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb [DDI sub-study]</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 21 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06647020</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies</measure>
    <time_frame>Days 1, 15, 28, and every 28 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-PF-06647020 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Q2W participants with objective response (single agent)</measure>
    <time_frame>Baseline, every 8 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of response rate (RR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of combination participants with objective response (PF-06647020 + avelumab)</measure>
    <time_frame>Baseline, every 8 weeks until disease progression or unacceptable toxicity up to 24 months</time_frame>
    <description>Number of participants with objective response based on assessment of overall response rate (ORR) and progression free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for PF-06380101</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve from Time Zero to end of dosing interval (AUCtau) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Concentration (Cmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Clearance (CL) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady state (Vss) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Reach Maximum Observed Concentration (Tmax) for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] for hu6M024 mAb</measure>
    <time_frame>Scheduled timepoints from Day 1 up to Day 84 and then every 28 days thereafter for up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (avelumab)</measure>
    <time_frame>Days 1, 15, 28, and every 28 days thereafter up to 24 months</time_frame>
    <description>Number of participants with the presence of anti-avelumab antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>PF-06647020 Q3W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug infused over 60 minutes once every 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug-drug interaction (DDI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06647020 combined with fluconazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06647020 Q2W</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational drug infused over 60 minutes once every 14 days (28 day cycle)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06647020 combined with Avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06647020 combined with Avelumab administered by infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 Q3W</intervention_name>
    <description>Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.
Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.</description>
    <arm_group_label>PF-06647020 Q3W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluconazole</intervention_name>
    <description>combination drug used for drug-drug interaction sub-study</description>
    <arm_group_label>Drug-drug interaction (DDI)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 Q2W</intervention_name>
    <description>Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined.
Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.</description>
    <arm_group_label>PF-06647020 Q2W</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06647020 combined with Avelumab</intervention_name>
    <description>Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.</description>
    <arm_group_label>PF-06647020 combined with Avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Q2W Inclusion Criteria:

          -  Diagnosis of platinum resistant or refractory OVCA having received 2 or fewer prior
             lines, or recurrent advanced NSCLC having received 3 or fewer prior lines

          -  Performance Status of 0, 1, or 2

          -  Adequate bone marrow, kidney, and liver function

        Q2W Exclusion Criteria:

          -  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
             mullerian tumors, unresolved bowel obstruction

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start

          -  Active and clinically significant bacterial, fungal, or viral infection

        Q3W Inclusion Criteria:

          -  Diagnosis of solid tumor that is advanced/metastatic and resistant to standard therapy
             or for whom no standard therapy is available

          -  Performance Status of 0 or 1

          -  Adequate bone marrow, kidney, and liver function

          -  Part 2 includes ovarian cancer, target expressing triple negative breast cancer and
             non small cell lung cancer patients

        Q3W Exclusion Criteria:

          -  OVCA pts excluded with any of the following: non-epithelial, including malignant mixed
             mullerian tumors, prior radiotherapy to pelvis/abdomen, pts with CA-125 only disease,
             unresolved bowel obstruction

          -  Brain metastases requiring steroids

          -  Major surgery, radiation therapy, or systemic anti-cancer therapy within 4 weeks of
             study treatment start

          -  Active and clinically significant bacterial, fungal, or viral infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Scottsdale Healthcare Hospitals DBA HonorHealth</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center Pharmacy</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Translational Research Unit (CTRU)</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Hospital and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medical Center, CCD</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University Infusion Center Pharmacy</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fairfax Radiology Consultants- Woodburn</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital Woodburn GYN Infusion Center</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital Woodburn Pharmacy</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Gynecologic Oncology and Pelvic Surgery Associates (MAGOPSA)</name>
      <address>
        <city>Annandale</city>
        <state>Virginia</state>
        <zip>22003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Schar Cancer Institute</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inova Loudon Hospital</name>
      <address>
        <city>Leesburg</city>
        <state>Virginia</state>
        <zip>20176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7661001&amp;StudyName=A%20Study%20Of%20PF-06647020%20For%20Adult%20Patients%20With%20Advanced%20Solid%20Tumors%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2014</study_first_submitted>
  <study_first_submitted_qc>August 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2014</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADC</keyword>
  <keyword>PF-06647020</keyword>
  <keyword>solid tumors</keyword>
  <keyword>tumors</keyword>
  <keyword>neoplasm metastasis</keyword>
  <keyword>TNBC</keyword>
  <keyword>triple negative breast cancer</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>advanced metastatic breast cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>OVCA</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

